Pfizer Inc. completed the acquisition of Seagen Inc., a biotechnology company specializing in cancer treatments, for approximately US$43 billion. This strategic move significantly enhances Pfizer's oncology portfolio, adding four approved cancer therapies and expanding its pipeline with 60 development programs.

To address U.S. Federal Trade Commission concerns, Pfizer donated the U.S. royalty rights for Bavencio (avelumab) to the American Association for Cancer Research.